Diligence memo · auto-generated · as of July 2, 2026
Civatech Oncology, Inc.
Civatech Oncology, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Civatech Oncology, Inc. operates in Pharma, based in MORRISVILLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Civatech Oncology, Inc. has raised $14M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.9M on 2021-11-11.
Most recent recorded round closed around 2021-11-11.
Valuation (modeled)modeled
Provath models Civatech Oncology, Inc. at approximately $133M (range $9.1M–$530M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.70× the median modeled value of Series A Pharma companies in 2019–2021 (24 peers) — value vs value, same stage and era. Within the normal band (70% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 4.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 8.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 72% of Pharma peers (310 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: Comet Therapeutics, Inc., RadImmune Therapeutics, Inc., Nanoscope Therapeutics, Inc., ZebiAI Therapeutics, Inc., Blue Note Therapeutics, Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.